The Valley Desk

ArticleBlood advancesPublished

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Blood advances
Published
Subject terms
Humans; Piperidines; Pyrazoles; Pyrimidines; Adenine; Treatment Outcome; Retrospective Studies; Aged; Aged, 80 and over; Middle Aged; Female; Male
PubMed ID
40353821
PubMed Central ID
PMC12311590
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal